09 Nov 21

ImmuNext and o2h discovery collaborate to progress first-in-...

o2h discovery is pleased to announce a productive multi FTE chemistry collaboration with ImmuNext to support their cutting-edge drug discovery program focused o...

02 Nov 21

o2h co work labs Hosted the World’s First Influencer B...

o2h co-work labs had a great time hosting the world’s first ‘influencer’ biotech bootcamp. The idea was to bring together a ‘biotech dirty dozen’, who...

15 Oct 21

o2h discovery is exhibiting at the ElRIG UK’s annual confe...

Delighted to announce that o2h discovery will be exhibiting at the ElRIG UK’s annual conference Drug Discovery 2021 on 19th – 20th Oct.  2020 was a yea...

08 Oct 21

o2h Ventures “Human Health SEIS Fund” Invests into Sanom...

Cambridge, UK, 28 Sept 2021: o2h Ventures is pleased to announce an investment into Sanome, a London-based biotech company combining biomarkers (health data poi...

27 Sep 21

o2h co-work Labs Launches the World’s First Influencer Bio...

Cambridge, UK, 23 Sept 2021: o2h co-work labs, a business unit of o2h Group, are absolutely delighted to launch the first ever influencer biotech bootcamp cover...

02 Sep 21

o2h group is supporting the upcoming BiotechBikers’ ne...

    We are excited to be supporting the upcoming BiotechBikers’ networking event cycle ride in Cambridge, UK. BiotechBikers brings together “bike-...

31 Aug 21

o2h Ventures makes it to the finals in the EISA Awards 2021&...

Delighted to share that o2h Ventures has been shortlisted as a finalist in the upcoming EISA Awards 2021 in the Best Newcomer category. The 2021 EISA Awards den...

13 Aug 21

o2h Ventures backed In4Derm enters into an exclusive license...

  VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited VYNE will have exclusive access t...

05 Aug 21

o2h Ventures ‘Knowledge Intensive Human Health EIS Fund’...

Cambridge, UK, 05 August 2021: o2h Ventures is delighted to announce an investment into BiVictriX Therapeutics, an emerging biotechnology company applying a no...

21 Jul 21

Digital brain biomarker company Monument Therapeutics raises...

Manchester, UK, June 28, 2021: Monument Therapeutics, a stratified medicine company, today announced it has raised £2.625 million in seed funding to spin out o...

05 Jul 21

Neophore closed £15.2m series B round successfully and expa...

Cambridge, UK, July 05 2021: o2h discovery is delighted to announce that one of its collaborators, NeoPhore Limited, a small molecule neoantigen immuno-oncology...

01 Jul 21

o2h Technology appoints serial entrepreneur Fiona Nielsen as...

Cambridge, UK, July 1 2021: o2h Technology, the software services business unit of the o2h group, today announced it has appointed Fiona Nielsen as Chief Operat...

23 Jun 21

o2h group is observing Kindness Day in memory of Shabu Thoma...

Shabu Thomas also known as the Chief Heart Officer will always be an integral part of the o2h family as he lives forever in the o2h group through his values and...

11 May 21

o2h Ventures backed In4Derm Announces a Strategic Partnershi...

Cambridge, UK, May 2021: o2h Ventures are excited to announce that In4Derm, backed by the fund managers “o2h human health EIS fund” has signed an Option and...

16 Apr 21

Sunil Shah, CEO of o2h ventures, wins the Cambridge Independ...

Cambridge, UK, 16th April 2021 We are delighted to announce that Sunil Shah of o2h ventures has won the prestigious award at the Cambridge Independent Science a...

17 Feb 21

Mill SciTech Park pre-planning application submitted

A pre-planning application for the development of the Mill SciTech Park, on the Hauxton Mill site in South Cambridgeshire has been submitted by o2h Group. The C...

28 Nov 20

o2h group in the finals of Cambridge Independent Science and...

We are delighted to share that o2h group are one of the finalists in the Cambridge Independent Science and Tech Awards 2020. The awards which are in their fourt...

23 Nov 20

Press Release – o2h group accomplished its goal of plantin...

Ahmedabad, India, 23rd Nov 2020: We are pleased to share that the o2h group has accomplished its goal of planting ten thousand trees across various regions of G...

12 Nov 20

o2h ventures launches the first HMRC approved knowledge inte...

o2h ventures is delighted to announce the launch of their HMRC approved knowledge intensive EIS fund, focusing on supporting the expansion of UK research and de...

23 Sep 20

o2h discovery is exhibiting at the 3rd RSC-BMCS / RSC-CICAG ...

Delighted to announce that o2h discovery will be exhibiting at the 3rd RSC-BMCS / RSC-CICAG Artificial Intelligence in Chemistry symposium. Following the succes...

23 Jun 20

o2h group announces Kindness Day in memory of Shabu Thomas

Shabu Thomas also known as the Chief Heart Officer will always be an integral part of the o2h family as he lives forever in the o2h group through his values and...

29 May 20

o2h community collaborated with The Ahmedabad Project to pla...

Earlier this year, the o2h community collaborated with The Ahmedabad Project to plant over 2000 trees in the community managed urban forest at Thaltej, Ahmedaba...

13 Apr 20

Fighting Coronavirus – an update on Remdesivir by Gile...

Great to see the recent early clinical trial results for Remdesivir showing some benefit in a small study of hospitalised infected patients.(1) The results of l...

25 Mar 20

Impacting COVID-19 – Opportunities for Chemists

Dear Chemists, We’re all aware of the situation we all are currently facing. We do these jobs for a love of chemistry and to steal a punchline from my old emp...

11 Mar 20

Delighted to Announce the 3rd o2h group collaborative innova...

Register Now! Download Brochure Watch Live on YouTube Innovation is the force that powers new industries, economies and the way we live. The model of innovation...

23 Feb 20

o2h community has completed the first stage of its campaign ...

We are pleased to share that o2h community has completed the first stage of its campaign to plant 10,000 trees. The announcement was made in Oct 2019 by Nilesh ...

16 Jan 20

o2h ventures portfolio company Exonate announces collaborati...

o2h Ventures portfolio company Exonate Announces a Collaboration with Janssen to develop a new eye drop for the treatment of retinal vascular diseases, includin...

13 Nov 19

Nilesh Dagia, COO, o2h discovery, wins the International Ins...

Colorado, USA, November 13 2019: We are absolutely delighted to announce that Nilesh Dagia, COO, o2h discovery, has won the Go Beyond Award in the Individual ca...

11 Nov 19

Sunil Shah, CEO, o2h discovery Wins Special Recognition Awar...

We are absolutely delighted to announce that Sunil Shah, CEO, o2h discovery, has won the Special Recognition Award at the industry leading OBN Awards 2019 event...

22 Oct 19

o2h discovery expands synthetic chemistry collaboration with...

Cambridge, UK, October 22 2019: o2h discovery is pleased to announce a significant expansion in its existing Synthetic Chemistry collaboration with Sosei Heptar...

17 Oct 19

o2h ventures makes it to the finals in the Tax Efficiency Aw...

Delighted to announce that the o2h ventures is a finalist for ‘The Best New Entrant’ in the 2019/20 Tax Efficiency Awards by Investment Week. The awards are...

20 Sep 19

Pleased to Announce the 13th Edition of o2h Women’s Op...

We are absolutely delighted to welcome you and the young talented graduates from all walks of life, to the 13th edition of o2h Women’s Open Day. We will share...

11 Sep 19

Cedilla Therapeutics and o2h discovery are pleased to announ...

Cambridge, UK/MA, September 11 2019: o2h discovery is pleased to announce multi FTE expansion to their synthetic chemistry collaboration with Cedilla Therapeuti...

12 Aug 19

Chemistry Process Optimization – an inevitable parameter f...

The cycle of a molecule from merely a structure on paper to a proven drug sold in the market is technically divided into 4 different Phases which can be further...

18 Jul 19

o2h ventures Makes an Investment in Small Pharma

Funding to enable further investigate an oral antidepressant based on a metabolite of ketamine and a 5HT2A agonist for treatment resistant depression. Identify ...

15 Jul 19

Q&A with Angel Investor Sunil Shah | The Sunday Times

  Sunil Shah, CEO of o2h ventures who recently won The Angel Investor of the Year by UKBAA was interviewed by Peter Evans, Enterprise Editor of The Sunday ...

08 Jul 19

Sunil Shah, o2h ventures wins Angel Investor of the Year

Cambridge, UK, 4th July 2019. We are delighted to announce Sunil Shah, CEO, o2h ventures, has won the prestigious UKBAA Angel Investor of the Year Award for his...

28 Jun 19

Sunil Shah, CEO, o2h ventures, makes it to final in the UKBA...

We are delighted to announce that Sunil Shah, CEO, o2h ventures, has been shortlisted for Angel Investor of the Year at the UKBAA Angel Investment Awards 2019! ...

18 Jun 19

Oxford Drug Design recieves over £8m in grant and equity in...

Oxford Drug Design (ODD) wins major funding awards from CARB-X, the UK Department of Health and Social Care (DHSC) and an equity investment led by o2h Ventures ...

10 Jun 19

Privitar Raises $40 Million Series B Funding Round Led by Ac...

LONDON & BOSTON, June 10 2019 — Privitar, the data privacy software company, announced it has closed a $40 million Series B funding round led by globa...

24 May 19

o2h Ventures makes it to the final in the Great EIS 25th Yea...

The Great EIS Banquet is a high-profile event run by the official group EISA to represent the EIS investing industry. This year will be a larger and higher prof...

01 Apr 19

Metrion Biosciences Closes Funding Round- o2h Ventures

Cambridge, UK, 01 April 2019: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, announced today ...

29 Mar 19

The o2h Therapeutics and AI Fund makes investment in early s...

Cambridge, UK, 28 March 2019. The o2h Therapeutics Fund & AI (“The Fund”), an early stage S/EIS fund investing in biotechnology therapeutic and related AI o...

28 Mar 19

2% off the initial fee for The o2h Therapeutics and AI S/EIS...

We are grateful to our early investors of The o2h Therapeutics and AI EIS Fund and should they wish to increase their participation in the upcoming deals we hav...

28 Mar 19

Press Release – The o2h Therapeutics Fund makes its fi...

Cambridge, UK, 14 March 2019. The o2h Therapeutics Fund & AI (“The Fund”), an early stage S/EIS fund investing in biotech therapeutic and related AI opp...

08 Mar 19

The o2h Innovation Conference 2019 14th March at Courtyard b...

o2h Ventures Limited, an investment firm based in Cambridge, UK, has now launched “the o2h Therapeutics Fund” an early stage SEIS and/or EIS fund backing bi...

31 Jan 19

o2h ventures limited has now launched the o2h therapeutics f...

o2h Ventures Limited, an investment firm based in Cambridge, UK, has now launched “the o2h Therapeutics Fund” an early stage SEIS and/or EIS fund backing b...

18 Oct 18

Arecor secures £6M investment for the clinical development ...

Cambridge, UK., 10 September 2018: Arecor Ltd (“the Company”), the UK-based leader in developing superior biopharmaceuticals through the application of an i...

22 Jun 18

Press Release – PhoreMost and o2h discovery collaborat...

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a collaboration w...

25 May 18

Stemnovate secures funding from angels led by o2h ventures

Stemnovate which is advancing 'organ on chip' technology has closed its seed investment round with a team of eight angels led by team of o2h ventures, whose co-...

09 May 18

Press release – o2h group acquires the 2.76 acre herit...

o2h acquires the 2.76 acre heritage Hauxton Mill site, Cambridge, UK with plans to develop it into the o2h SciTech Park to create one of the region’s most exc...

18 Apr 18

Press Release – Curza and o2h discovery announce a mul...

Curza Global, LLC and O2H DISCOVERY (O2H) are pleased to announce a multi FTE chemistry collaboration to support Curza as it drives its lead program targeting d...

17 Apr 18

Watch o2h Ventures CEO Sunil Shah feature in the British Bus...

In January, Exonate, one of o2h venture's investement, was approached by the British Business Bank to feature in a series of videos to highlight their Business ...

15 Mar 18

We are celebrating o2h Collaborative Innovation Conference, ...

o2h group announced to the world India’s first-of-a-kind conference for collaborative innovation in Science, Technology and Social Enterprise to be held in Ah...

14 Mar 18

o2h group Innovation day teaser

Dear Innovators, have you registered yourself for the o2h Innovation conference? Check the teaser for more....

10 Mar 18

o2h group invites you to Innovation day

o2h is celebrating Innovation day conference on 15th March at Hyatt, Vastrapur, Ahmedabad. We would like to invite you to this first-of-a kind innovation confer...

02 Nov 17

Chemistry in the Cloud™ – The World’s Fir...

The quest to positively benefit the lives of patients in the world of drug discovery means finding novel therapeutics for unmet medical needs. The biotech and p...

10 Oct 17

Arecor Announces License Agreement with Global Pharmaceutica...

Arecor Ltd (“the Company”), the leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation ...

04 Oct 17

IOTA Pharmaceuticals in £1.5M WINDOW Consortium Tackling Gl...

IOTA has been funded to establish a Glioblastoma “drug bank” as part of their membership of the WINDOW Consortium. More information about the WINDOW proj...

10 Aug 17

o2h group to attend these upcoming conferences

o2h Discovery are proud sponsors of the 19th RSC / SCI Medicinal Chemistry Symposium, 10 September 2017 15:00 - 13 September 2017 16:00, Cambridge, United King...

24 Jul 17

Exonate receives UK Angel Investment Award

NEWS RELEASE: Winners announced for UK Angel Investment Awards 2017 Thursday evening (6th July) saw over 300 leading entrepreneurs and early-stage business inve...

31 May 17

o2h ventures update: Oxford Drug Design secures £1.5M fina...

Oxford Drug Design Ltd (previously known as InhibOx), the leading computer aided drug design and 3D chemical database company, is pleased to announce that it ha...

13 May 17

o2h group update: Exonate receives Wellcome Trust funding to...

o2h update: Exonate, an early stage biotechnology company has been awarded a £4.9m Seeding Drug Discovery award by the Wellcome Trust to continue development ...

02 Nov 16

o2h discovery is pleased to announce a 10 FTE Synthetic Chem...

o2h Discovery is pleased to announce a 10 FTE Synthetic Chemistry collaboration with Heptares. Giles Brown, Director of Medicinal Chemistry: "Heptares is please...

16 Oct 16

Orfan Biotech, a company dedicated to developing small molec...

o2h Update: “Orfan Biotech, a company dedicated to developing small molecules for the treatment of Primary Hyperoxaluria. Orfan has a collaboration with o2h i...

16 Oct 16

o2h discovery are working with new Boston based start-up Arr...

o2h are working with new Boston based start-up Arrakis, supporting discovery efforts and making the seed funding stretch further! "Happy to be working with o2h,...

26 Sep 16

o2h community volunteers visit “Jeevan Dhara” – Old ag...

As a part of our community service seven of the o2h team went to “Jeevan Dhara” – an Old People's home based in Ahmedabad last Saturday.  The old people'...

28 Sep 15

o2h community, Community Service Project, HIV Orphanage, Ahm...

Given all the bad publicity our industry has had over the past few weeks which does not all reflect the passion of everybody I know in Biotech, I was very proud...

26 Apr 15

Investment in the seed round of Phoremost who have developed...

Investment in the seed round of Phoremost who have developed a next-generation phenotypic screening platform...

07 Apr 15

Happy 10th Birthday o2h group

Happy 10th birthday to o2h and a thank you to all our friends and colleagues that have worked with us over the years....

14 Jul 11

o2h discovery Announces Expanded Chemistry Collaboration Wit...

Executives from Heptares Therapeutics (Welwyn Garden City, UK) and o2h (Cambridge, UK) announced today an extension of the agreement under which o2h provides mu...